Addendum
Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87
Report documents
-
Addendum
Fingolimod (multiple sclerosis in children and adolescents) - Addendum to Commission A18-87
Dossier assessment
Indication:
Children and adolescents with highly active or rapidly evolving relapsing-remitting multiple sclerosis (RRMS)
Result of dossier assessment:
In one research question now also hint of added benefit in the category "health-related quality of life"; conclusion of dossier assessment A18-87 nonetheless unchanged
Press releases
Fingolimod: advantages for children and adolescents with highly active RRMS requiring treatment switch
Subsequently submitted data on quality of life are informative / added benefit in one of four patient groups
Additional information
Federal Joint Committee (G-BA)
2019-06-20 A G-BA decision was published.
Project details
- Project no.
- A19-42
- Commission
- Commission awarded on 06.05.2019 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Head and nerves
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Fingolimod (multiple sclerosis) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed